ArticleClinical and vaccine immunology : CVI2011
Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Clinical Characteristics and Diagnostic Challenges of COVID-19: An Update From the Global Perspective.Frontiers in public health · 2020Pooled it
- Detection and complete genome characterisation of bat coronaviruses from Ghana.Archives of virology · 2026Article
- COVID-19 prediction based on hybrid Inception V3 with VGG16 using chest X-ray images.Multimedia tools and applications · 2023Article
- Mass screening is a key component to fight against SARS-CoV-2 and return to normalcy.Medical review (2021) · 2022Review
- Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections.Frontiers in microbiology · 2022Article
- Recent advances in immunoassay technologies for the detection of human coronavirus infections.Frontiers in cellular and infection microbiology · 2022Review
- Editorial: Human coronavirus research: 20 years since the SARS-CoV outbreak.Frontiers in microbiology · 2022Article
- Development of a Novel Double Antibody Sandwich ELISA for Quantitative Detection of Porcine Deltacoronavirus Antigen.Viruses · 2021Article
- Dual electrochemical sensing of spiked virus and SARS-CoV-2 using natural bed-receptor (MV-gal1).Scientific reports · 2021Article
- MOV10 Helicase Interacts with Coronavirus Nucleocapsid Protein and Has Antiviral Activity.mBio · 2021Article
- Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.Molecules (Basel, Switzerland) · 2021Review
- Assessment and Management of Diabetic Patients During the COVID-19 Pandemic.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Monitoring Coronavirus Disease 2019: A Review of Available Diagnostic Tools.Frontiers in public health · 2021Review
- Laboratory diagnosis of novel corona virus (2019-nCoV)-present and the future.The Indian journal of tuberculosis · 2020Review
- The outlook for diagnostic purposes of the 2019-novel coronavirus disease.Journal of cellular physiology · 2020Review
- Laboratory diagnosis of emerging human coronavirus infections - the state of the art.Emerging microbes & infections · 2020Review
- Seasonal coronavirus protective immunity is short-lasting.Nature medicine · 2020Article
- COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2.Diagnostics (Basel, Switzerland) · 2020Review
- Laboratory Diagnosis of COVID-19: Current Issues and Challenges.Journal of clinical microbiology · 2020Article
- Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.Antiviral research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human coronaviruses (HCoVs) are responsible for respiratory tract infections ranging from common colds to severe acute respiratory syndrome. HCoV-NL63 and HCoV-229E are two of the four HCoVs that circulate worldwide and are close phylogenetic relatives. HCoV infections can lead to hospitalization of children, elderly individuals, and immunocompromised patients. Globally, approximately 5% of all upper and lower respiratory tract infections in hospitalized children are caused by HCoV-229E and HCoV-NL63. The latter virus has recently been associated with the childhood disease croup. Thus, differentiation between the two viruses is relevant for epidemiology studies. The aim of this study was to develop a double-antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) as a potential tool for identification and differentiation between HCoV-NL63 and HCoV-229E. The nucleocapsid (N) proteins of HCoV-NL63 and HCoV-229E were expressed in an Escherichia coli system and used to immunize mice in order to obtain monoclonal antibodies (MAbs) specific for each virus. Three specific MAbs to HCoV-NL63, one MAb specific to HCoV-229E, and four MAbs that recognized both viruses were obtained. After their characterization, three MAbs were selected in order to develop a differential DAS-ELISA. The described assay could detect up to 3 ng/ml of N protein and 50 50% tissue culture infective doses/ml of virus stock. No cross-reactivity with other human coronaviruses or closely related animal coronaviruses was found. The newly developed DAS-ELISA was species specific, and therefore, it could be considered a potential tool for detection and differentiation of HCoV-NL63 and HCoV-229E infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.